Affective alterations in patients with Cushing's syndrome in remission are associated with decreased BDNF and cortisone levels

E Valassi^{1,*}, I Crespo^{1,*}, B G Keevil², A Aulinas¹, E Urgell³, A Santos¹, P J Trainer⁴ and S M Webb¹

¹Endocrinology/Medicine Department, Hospital Sant Pau, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), IIB-Sant Pau, ISCIII and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain, ²Department of Clinical Biochemistry, University Hospital of South Manchester, Manchester, United Kingdom, ³Biochemistry Department, Hospital Sant Pau, Barcelona, Spain, and ⁴Department of Endocrinology, The Christie NHS Foundation Trust, Manchester, United Kingdom
*(E Valassi and I Crespo contributed equally to this work)

Correspondence should be addressed to E Valassi
Email
EValassi@santpau.cat

Abstract

Objective: Affective alterations and poorer quality of life often persist in patients with Cushing's syndrome (CS) in remission. Brain-derived neurotrophic factor (BDNF) regulates the hypothalamic–pituitary–adrenal axis (HPA) and is highly expressed in brain areas controlling mood and response to stress. Our aims were to assess affective alterations after long-term remission of CS and evaluate whether they are associated with serum BDNF, salivary cortisol (SalF) and/or cortisone (SalE) concentrations.

Subjects and methods: Thirty-six CS patients in remission (32 females/4 males; mean age ($\pm$ s.d.), 48.8 ± 11.8 years; median duration of remission, 72 months) and 36 gender-, age- and BMI-matched controls were included. Beck Depression Inventory-II (BDI-II), Center for Epidemiological Studies Depression Scale (CES-D), Positive Affect Negative Affect Scale (PANAS), State-Trait Anxiety Inventory (STAI), Perceived Stress Scale (PSS) and EuroQoL and CushingQoL questionnaires were completed and measured to evaluate anxiety, depression, stress perception and quality of life (QoL) respectively. Salivary cortisol was measured using liquid chromatography/tandem mass spectrometry (LC/TMS). BDNF was measured in serum using an ELISA.

Results: Remitted CS patients showed worse scores in all questionnaires than controls: STAI ($P < 0.001$), BDI ($P < 0.001$), CES-D ($P < 0.001$), PANAS ($P < 0.01$), PSS ($P < 0.01$) and EuroQoL ($P < 0.01$). A decrease in BDNF was observed in CS vs controls ($P = 0.038$), and low BDNF was associated with more anxiety ($r = -0.247$, $P = 0.037$), depression ($r = -0.249$, $P = 0.035$), stress ($r = -0.277$, $P = 0.019$) and affective balance ($r = 0.243$, $P = 0.04$). Morning salivary cortisone was inversely associated with trait anxiety ($r = -0.377$, $P = 0.040$) and depressed affect ($r = -0.392$, $P = 0.032$) in CS patients. Delay to diagnosis was associated with depressive symptoms (BDI-II: $r = 0.398$, $P = 0.036$ and CES-D: $r = 0.449$, $P = 0.017$) and CushingQoL scoring ($r = -0.460$, $P < 0.01$).

Conclusions: Low BDNF levels are associated with affective alterations in 'cured' CS patients, including depression, anxiety and impaired stress perception. Elevated levels of SalE might also be related to poor affective status in these patients.

European Journal of
Endocrinology
(2017) 176, 221–231

Introduction

Cushing's syndrome (CS) is a rare endocrine disorder caused by chronic exposure to cortisol excess (1). Patients with CS show poor neuropsychological status, including

depression, anxiety and mania, which also affect health-related quality of life (QoL) (2, 3, 4, 5, 6). Recent evidence indicates that some of the behavioral dysfunctions

Clinical Study	E Valassi, I Crespo and others	BDNF and salivary cortisone in 'cured' Cushing's syndrome	176:2	222
----------------	--------------------------------	---	-------	-----

observed in the active phase of CS do not fully revert after correction of hypercortisolism (7, 8, 9, 10, 11, 12, 13, 14, 15). In particular, an increased prevalence of affective alterations, such as anxiety, emotional lability and apathy, has been described in patients with Cushing's disease (CD) at an average of 11 years of remission, as compared not only with healthy subjects but also with patients who had been treated for non-functioning pituitary macroadenomas (16). As a matter of fact, recent magnetic resonance (MR) imaging studies showed structural and functional brain damage in CS patients for a long-term after remission, mainly at those brain regions, rich in glucocorticoid receptors (GR), which are involved in stress reactivity and emotional processing (17, 18, 19, 20). These findings suggest that previous over-exposure to cortisol may cause irreversible effects on brain, thus leading to sustained psychological symptomatology after eucortisolism is reached (21). Of note, Dorn *et al.* reported an inverse association between persistent psychopathology and morning cortisol values in CS patients in long-term remission, indicating that a sustained derangement of the hypothalamic–pituitary–adrenal axis after restoration of eucortisolism may increase the individual vulnerability to stressors (8).

Brain-derived neurotrophic factor (BDNF), a member of the nerve growth factor (NGF) family, is a prominent mediator of neuronal differentiation, survival and plasticity and is highly expressed in the hippocampus and prefrontal cortex, which constitute a neural circuitry controlling mood and response to stress (22). Decreased BDNF expression in these regions has been described in several models of rodents exposed to chronic stress and has been associated with depression-like behavior (23). In humans, serum BDNF levels are lower in stress-induced affective disorders, including major depression disorder (MDD), compared with healthy controls, and are increased by antidepressant treatment (22). Noteworthy, BDNF may be involved in the regulation of the hypothalamic–pituitary–adrenal axis (HPA) in that the intracerebroventricular administration of this neurotrophin enhances the expression of corticotrophin-releasing factor (CRF) in the hypothalamus of adult rats, leading to the elevation of plasma corticosterone levels (24).

Assessment of salivary cortisol (SalF), a surrogate for free serum cortisol (SerF), is routinely used as a biomarker of psychological stress and depressive symptoms (25) and has also been advocated in clinical practice as an accurate test to diagnose CS (26) or ascertain postoperative outcome in CD patients (27). Yet, because of the abundance in the

parotid gland of 11 β -hydroxysteroid dehydrogenase type 2 (11 β -HSD2), which converts cortisol (SalF) to cortisone (SalE), the latter is the most abundant glucocorticoid in saliva (28). Indeed, it has been recently demonstrated that salivary cortisone (SalE) is highly correlated to SerF concentrations under both basal and stimulated conditions, and, in contrast to SalF, is detectable even in the presence of low SerF levels (29, 30). These findings suggest that SalE could be more reliable than SalF in assessing the biological activity of cortisol. To the best of our knowledge, no data have been published thus far on SalE in CS patients in long-term remission.

We hypothesized that BDNF is decreased in 'cured' CS and modulates mood and stress perception in these patients. Moreover, given that SalE may be a more accurate surrogate marker of SerF than SalF, and serum cortisol is associated with psychological impairment in CS patients in long-term remission, we hypothesized that morning and late-night SalE concentrations are associated with altered emotional status in these patients.

Thus, the aim of this study was to examine the relationship between serum BDNF levels, depressive and anxiety symptoms, impairment of stress perception and emotional status, as well as poor HRQoL, in patients treated for CS. In addition, we aimed at determining if there was an association between SalF and/or SalE, as assessed by a highly sensitive and specific liquid chromatography/tandem mass spectrometry (LC/TMS) method, and depressive symptoms as well as BDNF values in our patients.

Methods

Subjects

We studied 36 patients with Cushing's syndrome in remission (32 females and 4 males; mean age ($\pm$ S.D.), 48.83 $\pm$ 11.8 years; 20 females (63%) were premenopausal) who were included successively in our study while attending the endocrine clinic at the Hospital Sant Pau, Barcelona (Spain). They were matched for age, gender and body mass index (BMI) with 36 controls who were recruited through advertisement at the blood donor center of the Hospital Sant Pau, Barcelona (Spain) (Table 1).

The diagnosis of CS was made after clinical, biochemical and radiological evaluation, based on internationally agreed guidelines. All patients had abnormal values on at least two of the following tests: elevated UFC, late-night salivary or serum cortisol, 1-mg overnight dexamethasone suppression test (ODST) or

Clinical Study	E Valassi, I Crespo and others	BDNF and salivary cortisone in 'cured' Cushing's syndrome	176:2	223
----------------	--------------------------------	---	-------	-----

Table 1 Clinical characteristics of CS patients in remission and healthy controls. All values are expressed as mean $\pm$ s.d. or as *n* (%).

Characteristics	CS in remission (<i>n</i> =36)	Healthy controls (<i>n</i> =36)	<i>P</i> value
Gender (female/male)	32/4	32/4	0.99
Age (years)	48.8 $\pm$ 11.8	48.8 $\pm$ 11.7	0.99
Body mass index (BMI, kg/m ²)	27 $\pm$ 4.7	26.1 $\pm$ 5.7	0.46
Origin of CS:		–	
Pituitary adenoma	25 (69%)		
Adrenal adenoma	11 (31%)		
Transsphenoidal surgery	25 (69%)	–	
Radiotherapy	6 (24%)	–	
Previous medical treatment with steroidogenesis inhibitors	20 (56%)	–	
Delay to diagnosis (months)	24 (41.7)	–	
Duration of remission (months)	72 (153.7)	–	
Time from diagnosis to remission (months)	12 (6)	–	
Gonadotropin deficiency	3 (8%)	–	
Growth hormone deficiency	5 (14%)	–	
Hypothyroidism	5 (14%)	–	
Salivary cortisol (nmol/L; mean $\pm$ s.d.(range))			
Morning	5.8 $\pm$ 3.9 (1.4–14.6)	6.3 $\pm$ 4.1 (0.8–21.8)	0.63
Late-night	1.6 $\pm$ 1.1 (0.8–4.9)	1.2 $\pm$ 0.9 (0.8–4.8)	0.16
Salivary cortisol (nmol/L; mean $\pm$ s.d.(range))			
Morning	16.5 $\pm$ 9.9 (3.1–39.6)	17.1 $\pm$ 9.2 (0.8–42.7)	0.81
Late-night	5.9 $\pm$ 6 (0.8–26.5)	4.4 $\pm$ 3.2 (0.8–12.9)	0.23
Cortisol diurnal rhythm (CDR)	3.6 $\pm$ 2	3.7 $\pm$ 2	0.71
Morning SalF/SalE ratio	0.39 $\pm$ 0.19	0.37 $\pm$ 0.2	0.65
Midnight SalF/SalE ratio	0.38 $\pm$ 0.31	0.32 $\pm$ 0.23	0.45

*Values are expressed as median (interquartile range).

48-h 2-mg/day low-dose dexamethasone suppression test (LDDST).

Twenty-five patients had Cushing's disease (CD) due to a microadenoma (*n*=22) or a macroadenoma (*n*=3). The remaining 11 patients had an adrenal adenoma. All the CD patients underwent transsphenoidal surgery (TSS) from 12 to 288 months previously (median: 78 months), and 6 of them (24%) also received radiotherapy from 18 to 96 months after unsuccessful surgery (*n*=2) or relapse (*n*=4) (median: 54 months). All the patients diagnosed with an adrenal adenoma underwent adrenalectomy from 12 to 312 months previously (median: 54 months).

Twenty patients (56%) received preoperative treatment with steroidogenesis inhibitors to control clinical symptoms of hypercortisolism from 1 to 22 months (median: 4.6 months) prior to surgery.

Delay to diagnosis was defined as the time elapsed from onset of symptoms, as referred by patients, and final diagnosis of CS.

CS was considered in remission if either adrenal insufficiency was demonstrated (basal morning cortisol <1002 nmol/L (<4 μ g/dL) and/or undetectable 24-h free urinary cortisol) or morning cortisol suppression (<50 nmol/L and <1.8 μ g/dL) after 1 mg dexamethasone overnight was observed. Thirty patients (83%) had

received hydrocortisone (HC) replacement for a median of 9 months (range: 3–60 months) after surgery. At the time of study entry, no patient was on HC, for a median of 94 months (range: 5–204 months). Active hypercortisolism was ruled out in all the patients. Duration of remission was defined as the time elapsed from diagnostic confirmation of remission to study entry.

At study entry, all the subjects were evaluated for possible pituitary insufficiency. Three patients (8%) had growth hormone deficiency (GHD) and were on replacement with recombinant human GH; five women (14%) were gonadotropin deficient and on estrogen/progesterone hormone replacement; and five (14%) were hypothyroid, three due to TSH deficiency and two due to primary hypothyroidism (all on L-thyroxine replacement).

Exclusion criteria were active disease, patients with ascertained adrenal insufficiency (i.e. morning cortisol values below 5 μ g/dL or stimulated cortisol levels below 18 μ g/dL) (31) and/or taking replacement therapy with hydrocortisone, diabetes mellitus, diagnosis of major depression disorder or other psychiatric condition, and patients taking more than one psychoactive drug (benzodiazepines and selective serotonin reuptake inhibitors–SSRIs).

Clinical Study	E Valassi, I Crespo and others	BDNF and salivary cortisone in 'cured' Cushing's syndrome	176:2	224
----------------	--------------------------------	---	-------	-----

During the study visit, patients and controls underwent a fasting blood drawing for the measurement of BDNF. All the subjects were asked to report their daily habits (awakening, lunch/dinner time and bed-time); they used to wake up around 7.30–8 and go to sleep around midnight. They were also given four commercially available cotton devices (Salivette, Sarstedt, Numbrecht, Germany) for collection of morning (between 07:30 and 08:00 h) and late-night (23:30 and 24:00 h) saliva samples on two consecutive days. Subjects were instructed to refrain from brushing their teeth, smoking, eating or drinking other than water for at least 60 min before sampling. They were also instructed to store the Salivettes, after saliva sampling, at 4°C in a home refrigerator and send back by mail within 7 days. The cortisol diurnal rhythm (CDR) was calculated as the ratio between morning salivary cortisol to midnight salivary cortisol. A normal CDR was defined by morning/midnight ratio of salivary cortisol >2 (32).

All subjects gave full informed consent, and the study was approved by the local ethics committee (CEIC, Hospital Sant Pau, Barcelona).

Assays

Salivary cortisol was measured by liquid-chromatography–tandem mass spectrometry (LC/TMS). Salivary cortisol (SalF) and salivary cortisone (SalE) were measured with a LC–MS/MS assay with lower limits of quantitation 0.39 nmol/L (SalF) and 0.78 nmol/L (SalE); intra-assay CVs of less than 9.3% and less than 7.9%; and interassay CVs of less than 9.7% and less than 10.3% at 1.8–52.2 nmol/L of SalF and 3.6–96 nmol/L of SalE respectively (28, 29). The ratio SalF/SalE was calculated as a marker of 11 β -HSD2 activity (29).

Brain-derived neurotrophic factor (BDNF) measurement in serum was performed by a Quantikine ELISA (R&D Systems Europe LTD). The limit of detection was less than 20 pg/mL. Interassay variation was 7.6–11.3% and intra-assay variation 3.8–6.2%.

Measurement of affective state

State-Trait Anxiety Inventory

State-Trait Anxiety Inventory (STAI) is a self-reported measure that includes two subscales to evaluate two types of anxiety: state anxiety (anxiety related to current events) and trait anxiety (anxiety as a personal characteristic). Each

subscale has 20 questions with a four-point scale ranging from 0 to 3. The total score for each subscale can range from 0 to 60. Higher scores indicate higher levels of anxiety (33).

Beck Depression Inventory-II

Beck Depression Inventory-II (BDI-II) is a self-reported measure of the severity of depressive symptoms. It has 21 items with a four-point scale ranging from 0 to 3. The total score is the sum of each item rating and can range from 0 to 63. Higher scores indicate more severe depressive symptoms. The BDI-II can be separated into affective and somatic dimensions (34, 35).

Center for Epidemiological Studies Depression Scale

Center for Epidemiological Studies Depression Scale (CES-D) includes 20 items measuring subject frequency rate of depressive symptoms on a four-point scale ranging from 0 to 3. CES-D can be separated into four subscales assessing: (1) depressed affect, (2) vegetative depression, (3) loss of wellbeing and (4) interpersonal relationships. Higher scores indicate more frequency of depressive symptoms (36).

Positive and Negative Affective Schedule

Positive and Negative Affective Schedule (PANAS) is a self-reported measure of positive and negative emotions in the last week. PANAS consists of 20 words (10 reflect positive affect and 10 negative affect), which are rated from 1 to 5. Higher score indicates more intensity in the emotion. The affective balance (total score) is calculated as the difference between positive affect and negative affect (37).

Perceived Stress Scale

Perceived Stress Scale (PSS) measures the perception of situations appraised as unpredictable or uncontrollable over the last month and includes 14 items with a 5-point response scale. A higher score indicates a higher level of perceived stress (38).

Measurements of Quality of Life (QoL)

EuroQoL

EuroQoL is a generic questionnaire of QoL that is divided into 2 parts. EuroQoL-5D profile evaluates five health dimensions (mobility, self-care, usual activities, pain/

discomfort and anxiety/depression) with a single item with three possible answers (having no problems, having some or moderate problems and being unable to do/having extreme problems). EuroQoL-VAS is a visual analogue scale that evaluates the self-perception of current health (39), ranging from 0 (worst possible) to 100 (best possible QoL).

CushingQoL

CushingQoL is a disease-generated questionnaire, which consists of 12 items referring to problems relevant to CS patients. Each item has five categories of response related to frequency and degree of agreement with the sentence. The total score is the sum of each item-rating (range 12–60) and higher scores indicate better QoL (6, 14).

Statistical analysis

Data were analyzed using SPSS 21.0 statistical package for Windows (SPSS Inc.) with a level of significance of $P < 0.05$. All quantitative data are expressed as mean $\pm$ s.d. (Gaussian distribution) or as median (interquartile range) (non-Gaussian distribution). Data distribution was analyzed by the Kolmogorov–Smirnov test. Comparisons between the two groups were performed using Student's *t*-test and Mann–Whitney *U* test. Correlations among variables were studied using Pearson's correlation coefficient for parametric measures and Spearman's rho for non-parametric measures. Furthermore, stepwise multiple linear regression analyses were performed to assess potential predictors of CushingQoL scoring. A logarithmic transformation of 'delay to diagnosis', a variable which was not normally distributed, was performed before entering it to a multiple regression model.

Results

Hormone parameters

No differences in either SalF or SalE were observed between CS patients and healthy controls. The ratio SalF a.m./SalF p.m. and ratio SalF/SalE were also similar in CS and controls (Table 1).

BDNF values were significantly lower in CS patients than controls (433.5 ± 278.8 pg/mL vs 602.8 ± 391.1 pg/mL, $P = 0.038$) (Fig. 1).

No differences in BDNF levels were found between patients with CD and patients with an adrenal adenoma or patients receiving surgery alone as compared with those who also underwent radiotherapy.

Figure 1

BDNF levels were significantly lower in CS patients in remission (433.5 ± 278.8 pg/mL) as compared with healthy controls (602.8 ± 391.1 pg/mL) ($*P = 0.038$).

Affective state and QoL

CS patients showed both higher state and trait anxiety scores than controls (state, 22.9 ± 13.4 vs 12.2 ± 8.1 ; trait, 25.8 ± 13.7 vs 14.9 ± 8.5 ; $P < 0.001$ for both comparisons).

Table 2 Affective state in CS patients in remission and healthy controls.

Questionnaires	CS in remission (n=36)	Healthy controls (n=36)	P value
STAI			
Anxiety state	22.9 ± 13.4	12.2 ± 8.1	<0.001
Anxiety trait	25.8 ± 13.7	14.9 ± 8.5	<0.001
BDI-II			
Total score	11.3 ± 10.2	3.4 ± 2.9	<0.001
Affective dimension	6.7 ± 1.3	1.7 ± 0.3	<0.001
Somatic dimension	4.6 ± 0.5	1.7 ± 0.3	<0.001
CES-D			
Total score	16 ± 13.2	6.5 ± 6.4	<0.001
Depressed affect	4.6 ± 0.9	1.4 ± 0.4	0.001
Vegetative depression	5.3 ± 0.9	2 ± 0.4	0.001
Loss of well-being	5.5 ± 0.6	2.9 ± 0.5	0.002
Interpersonal relationship	0.56 ± 1.2	0.25 ± 0.5	0.185
PANAS			
Affective balance (or total score)	7.5 ± 2.4	19.3 ± 1.8	<0.001
Positive affect	26 ± 8.7	32.9 ± 9.2	0.002
Negative affect	18.6 ± 9.4	13.6 ± 3.7	0.005
PSS			
Total score	24.94 ± 9.8	17.56 ± 8	0.001

BDI-II, Beck Depression Inventory-II; CES-D, Center for Epidemiological Studies Depression Scale; PANAS, Positive and Negative Affective Schedule; PSS, Perceived Stress Scale; STAI, State-Trait Anxiety Inventory.

Clinical Study	E Valassi, I Crespo and others	BDNF and salivary cortisone in 'cured' Cushing's syndrome	176:2	226
----------------	--------------------------------	---	-------	-----

Table 3 Significant correlations between questionnaires and clinical parameters.

Questionnaires	Clinical parameters, <i>r</i>		
	BDNF (pg/mL)	Morning salivary cortisone (SalE) (nmol/L)	Delay to diagnosis (months)
STAI			
Anxiety state			
Anxiety trait	−0.247*	−0.377*	
BDI-II			
Total score			0.398*
Affective dimension	−0.249*		
Somatic dimension			
CES-D			
Total score			0.449*
Depressed affect		−0.392*	
Vegetative depression			
Loss of wellbeing			
Interpersonal relationship			
PANAS			
Affective balance (total score)	0.243*		
Positive affect	0.295*		
Negative affect			
PSS			
Total score	−0.277*		
CushingQoL			
Total score			−0.460**

* $P < 0.05$; ** $P < 0.01$.

(Table 2). Total score of BDI-II was higher in CS patients than controls, indicating more depressive symptoms (11.3 ± 10.2 vs 3.4 ± 2.9 , $P < 0.001$). CS patients scored worse on affective and somatic subscales of BDI-II than controls (affective, 6.7 ± 1.3 vs 1.7 ± 0.3 ; somatic, 4.6 ± 0.5 vs 1.7 ± 0.3 ; $P < 0.001$ for both comparisons) (Table 2). Twenty-four CS patients (67%) showed minimal symptoms, 4 (11%) mild symptoms, 5 (14%) showed moderate symptoms and three (8%) severe symptoms of depression.

CS patients also reported greater total depressive symptoms than controls using the CES-D (16 ± 13.2 vs 6.5 ± 6.4 ; $P < 0.001$). CS patients scored higher on subscales of depressed affect, vegetative depression and loss of wellbeing compared to healthy controls (depressed affect, 4.6 ± 0.9 vs 1.4 ± 0.4 ; vegetative depression, 5.3 ± 0.9 vs 2 ± 0.4 ; loss of wellbeing, 5.5 ± 0.6 vs 2.9 ± 0.5 ; $P < 0.01$ for all comparisons). No differences in the subscale of interpersonal relationships were found between CS and controls. On PANAS, the affective balance score was

lower in CS patients than healthy controls (7.5 ± 2.4 vs 19.3 ± 1.8 ; $P < 0.001$). CS patients scored higher on negative affect and lower on positive affect than controls, as assessed by PANAS (negative affect, 18.6 ± 9.4 vs 13.6 ± 3.7 ; positive affect, 26 ± 8.7 vs 32.9 ± 9.2 ; $P < 0.01$ for both comparisons) (Table 2).

Total score of PSS was higher in CS patients than healthy control (24.9 ± 9.8 vs 17.6 ± 8 ; $P < 0.01$), indicating greater stress perception (Table 2).

CS patients showed poorer QoL than healthy controls, as assessed by EuroQoL-VAS (70.9 ± 19.8 vs 84.5 ± 14.5 ; $P < 0.01$). Cushing QoL in CS patients was 40 ± 9.9 .

No differences in these parameters were observed between CD patients as compared with those with an adrenal adenoma.

Relationship between hormone values, affective state and QoL

BDNF levels were negatively correlated with the trait anxiety score of STAI ($r = -0.247$, $P = 0.037$), the affective dimension score of BDI-II ($r = -0.249$, $P = 0.035$) and the perception of stress ($r = -0.277$, $P = 0.019$) measured by PSS. Moreover, BDNF was correlated with the affective balance and positive affect of PANAS (affective balance, $r = 0.243$, $P = 0.04$; positive affect, $r = 0.295$, $P = 0.012$). These associations remained significant after correcting for age (Table 3).

There was an inverse correlation between level of morning salivary cortisone and scores on trait anxiety of STAI ($r = -0.377$, $P = 0.040$) and depressed affect of CES-D ($r = -0.392$, $P = 0.032$) (Table 3 and Fig. 2). Midnight SalF/SalE ratio was negatively correlated with BDNF levels ($r = -0.401$, $P = 0.035$) in CS patients but not in controls.

On the other hand, delay to diagnosis was related to the total score of BDI-II and total score of CES-D (BDI-II: $r = 0.398$, $P = 0.036$ and CES-D: $r = 0.449$, $P = 0.017$), two measurements of depressive symptoms and CushingQoL scores ($r = -0.460$, $P < 0.01$) (Table 3 and Fig. 3). These correlations lost significance after correction for age. We did not find any correlations between duration of remission and both affective state and QoL measurements.

When CushingQoL scoring was entered as a dependent variable and age, delay to diagnosis and total score of BDI-II as independent variables in a forward stepwise regression model, total score of BDI-II was the only predictor of CushingQoL ($\beta = -0.647$; $P < 0.001$) in CS patients.

Figure 2

Morning salivary cortisone was inversely associated with (A) anxiety trait of State-Trait Anxiety Inventory (STAI) ($r=-0.377$, $P=0.040$) and (B) depressed affect of Center for Epidemiological Studies Depression Scale (CES-D) ($r=-0.392$, $P=0.032$) in CS patients in remission.

Discussion

We have shown that CS patients in long-term remission have low levels of circulating BDNF, which are associated with more anxiety trait, depression and perceived stress, and less affective balance and positive affect, regardless of age and SalF/Sale concentrations. These findings support the hypothesis that BDNF may be a marker of affective state and stress perception in CS patients, even after long-term correction of hypercortisolism. In addition, we have shown that Sale levels early in the morning are inversely associated with anxiety trait and depressed affect.

Figure 3

Delay to diagnosis was (A) inversely associated with CushingQoL score ($r=-0.460$, $P<0.01$) and (B) positively with the total score of the Beck Depression Inventory-II (BDI-II) ($r=0.398$, $P=0.036$).

BDNF is an important regulator of the HPA axis adaptive response to stress (40), and its expression is reduced in animal models of depression at the level of the hippocampus and prefrontal cortex, both being important brain regions involved in stress responsivity and emotional functioning (41). In humans, BDNF is being increasingly considered as a biomarker of depression (22). Its serum concentrations decrease in mood disorders, with a negative association with the severity of depression and normalize after successful treatment; this finding being validated after meta-analyses of multiple studies (22, 42, 43, 44). Consistently, we have shown an association between low BDNF and impaired mood

Clinical Study	E Valassi, I Crespo and others	BDNF and salivary cortisone in 'cured' Cushing's syndrome	176:2	228
----------------	--------------------------------	---	-------	-----

and stress perception in remitted CS patients but not in matched controls.

BDNF levels have not been studied in patients with active CS thus far but *in vivo* experiments have demonstrated a negative association between chronic exposure to corticosterone and BDNF expression in the frontal cortex of rats, which is associated with atrophy of the limbic structures regulating the response to stress (40, 45). Of note, frontal cortical thinning has been previously described in CS patients after long-term remission (19). Interestingly, we have shown a negative association between BDNF and midnight SalF/SalE ratio in our CS patients only. Thus, it may be intriguing to speculate that the observed decrease in BDNF may be one of the persisting abnormalities in 'cured' CS patients after the achievement of eucortisolism and may reflect irreversible structural and/or functional changes in neural circuitries as a consequence of previous exposure to cortisol excess. Of note, serum BDNF has been found to be low in patients who suffered a traumatic brain injury and positively related to cognitive functioning in these subjects, implying that this neurotrophin may be a biomarker of neuronal damage (46).

It is important to highlight that whether serum BDNF entirely reflects BDNF levels in the human brain is still a matter of debate. Although BDNF protein passes the blood–brain barrier (47), and a positive correlation between circulating BDNF concentrations in blood and brain-tissue BDNF levels has been described across species (48), this neurotrophin is also secreted by several peripheral cells, including platelets, leukocytes and endothelial cells (47). Thus, the impact of either central or peripheral BDNF source on our results cannot be determined with certainty. However, some authors have documented a significant relationship between circulating BDNF and some structural/functional brain characteristics in humans (49, 50, 51). Erickson *et al.* found that low BDNF levels in serum were associated with age-related decline in hippocampal volume and memory performance (49), whereas Lang *et al.* demonstrated that serum BDNF was related to intracerebral concentrations of N-acetylaspartate, a marker of neuronal integrity, which they measured in healthy subjects using proton magnetic resonance spectroscopy (50). Moreover, Dalby *et al.* described a negative association between circulating BDNF concentrations in the blood and white matter integrity, as assessed using diffusion tensor imaging, in the prefrontal cortex of both depressed and healthy subjects (51). Further evidence is needed to confirm our correlative data, and

conclusively assess to which degree serum BDNF reflects BDNF levels in the brain.

Another important finding of our study is that morning SalE is inversely related to depressed affect and anxiety trait in 'cured' Cushing's syndrome only, in contrast with SalF, which was not associated with any psychological dimensions in the groups analyzed. Recent evidence suggests that SalE, the predominate glucocorticoid in saliva, may reflect more accurately fluctuations in serum free cortisol (SeF) than SalF (30) and, therefore, may be useful to measure the biological activity of cortisol in several conditions associated with HPA axis dysregulation, including CS and mood disorders (28). Although SalF assessment is clinically used in both endocrine and psychiatric conditions as a diagnostic marker of hypercortisolism (26) and psychological stress (25) respectively, data on SalE in these contexts are scanty. To the best of our knowledge, this is the first time that SalE has been measured in patients who suffered CS and is related to residual morbidity. Moreover, use of LC/TMS to simultaneously assess both SalF and SalE in saliva is a strength of our study, in that this technique allows to overcome the cross-reactivity of cortisone, which has been described to interfere with the accurate measurement of SalF in the most frequently used immunoassays (28).

Although levels of SalE were similar between CS patients in remission and controls, we documented an inverse relationship between morning SalE and measures of mood dysfunction. HPA hypoactivity has been described in patients with atypical depression as well as several stress-related states showing an heterogeneous spectrum of depressive symptoms, such as chronic fatigue syndrome and fibromyalgia (52). Dorn *et al.* found that atypical depression was the most prevalent psychopathology in CS patients one year after remission, and lower morning baseline concentrations of cortisol were related to higher numbers of psychological symptoms, including anxiety, depression and psychoticism (3). This finding led the authors to speculate that derangement of the HPA axis, namely low CRH production or relative glucocorticoid deficiency, may persist for a long term despite correction of hypercortisolism and contribute to the maintenance of affective disorders in remitted CS (3, 53). We cannot support this hypothesis, because we did not extensively evaluate the HPA axis responsiveness under stimulated conditions. In addition, although we cannot exclude that some of our patients had relative glucocorticoid deficiency at study entry, hydrocortisone replacement was withdrawn in all of them, after recovery of the HPA axis was confirmed by an ACTH stimulation test (31).

Although our CS patients in remission showed clear depressive symptomatology and scored worse than controls on several scales assessing mood and affect, they did not meet the criteria for clinical depression, in line with the results of prior studies (11, 16, 54). This indicates that patients previously exposed to cortisol excess maintain an increased vulnerability to stress, leading to a longstanding 'subtle', but nevertheless clinically relevant, psychopathology. The pathogenesis of this is probably multifactorial, not only including dysregulated HPA axis (44) but also coping strategies and personality traits (16), impaired decision making (19), previous stress induced by suffering a chronic disease (5) and structural/functional alterations of brain regions controlling emotional functioning and stress modulation (17).

In our study, delay to diagnosis was related with depressive symptoms and QoL. Recent evidence suggests that early diagnosis and treatment are clinical predictors of QoL after achieving remission of CD (55). However, we have found that depressive symptomatology is the main negative predictor of QoL rather than delay to diagnosis. Thus, our data suggest that affective alterations, mainly depressive symptoms, might play a pivotal role in affecting patients' wellbeing and daily living after long-term remission, in line with findings observed in active patients (56). Therefore, screening for subtle affective alterations should be included in the regular follow-up of CS patients.

This study has several limitations. The small sample size, an unavoidable drawback of the studies on rare diseases, may also account for the lack of significance in some of the analyses performed. However, these are important preliminary data suggesting that serum BDNF and salivary cortisone might be helpful markers of affective alterations in 'cured' CS patients. Another limitation is its crosssectional design, which prevented us from inferring causality from these data. In addition, because BDNF plays a role in the regulation of energy homeostasis and food intake, circulating BDNF levels in serum could be influenced by other factors, including body weight and nutritional habits (57).

In conclusion, altered affectivity, mainly anxiety, depressive symptoms, negative affect and stress, persists for a long-term in patients previously treated for CS, and SalE concentrations might be a potential marker of the affective status in these patients. Low levels of BDNF could be involved in the pathophysiology of the affective alterations observed in patients with CS in remission.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported in part by Novartis through an Investigator Initiated Trial. E V is recipient of a 'Juan de la Cierva' postdoctoral grant from the Spanish Ministry of Economy and Competitiveness (MINECO).

Acknowledgments

The authors are indebted to all the subjects participating in this study.

References

- Newell-Price J, Bertagna X, Grossman AB & Nieman LK. Cushing's syndrome. *Lancet* 2006 **367** 1605–1617. (doi:10.1016/s0140-6736(06)68699-6)
- Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB *et al.* Diagnosis and complications of Cushing's syndrome: a consensus statement. *Journal of Clinical Endocrinology and Metabolism* 2003 **88** 5593–5602. (doi:10.1210/jc.2003-030871)
- Dorn LD, Burgess ES, Dubbert B, Simpson SE, Friedman T, Kling M, Gold PW & Chrousos GP. Psychopathology in patients with endogenous Cushing's syndrome: 'atypical' or melancholic features. *Clinical Endocrinology* 1995 **43** 433–442. (doi:10.1111/j.1365-2265.1995.tb02614.x)
- Kelly WF, Kelly MJ & Faragher B. A prospective study of psychiatric and psychological aspects of Cushing's syndrome. *Clinical Endocrinology* 1996 **45** 715–720. (doi:10.1046/j.1365-2265.1996.8690878.x)
- Sonino N, Fava GA, Raffi AR, Boscaro M & Fallo F. Clinical correlates of major depression in Cushing's disease. *Psychopathology* 1998 **31** 302–306. (doi:10.1159/000029054)
- Webb SM, Badia X, Barahona MJ, Colao A, Strasburger CJ, Tabarin A, van Aken MO, Pivonello R, Stalla G, Lamberts SW *et al.* Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. *European Journal of Endocrinology* 2008 **158** 623–630. (doi:10.1530/EJE-07-0762)
- Valassi E, Crespo I, Santos A & Webb SM. Clinical consequences of Cushing's syndrome. *Pituitary* 2012 **15** 319–329. (doi:10.1007/s11102-012-0394-8)
- Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW & Chrousos GP. The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism. *Journal of Clinical Endocrinology and Metabolism* 1997 **82** 912–919. (doi:10.1210/jc.82.3.912)
- Heald AH, Ghosh S, Bray S, Gibson C, Anderson SG, Buckler H & Fowler HL. Long-term negative impact on quality of life in patients with successfully treated Cushing's disease. *Clinical Endocrinology* 2004 **61** 458–465. (doi:10.1111/j.1365-2265.2004.02118.x)
- Van Aken MO, Pereira AM, Biermasz NR, van Thiel SW, Hoftijzer HC, Smit JWA, Roelfsema F, Lamberts SWJ & Romijn JA. Quality of life in patients after long-term biochemical control of Cushing's disease. *Journal of Clinical Endocrinology and Metabolism* 2005 **90** 3279–3286. (doi:10.1210/jc.2004-1375)
- Sonino N, Bonnini S, Fallo F, Boscaro M & Fava GA. Personality characteristics and quality of life in patients treated for Cushing's syndrome. *Clinical Endocrinology* 2006 **64** 314–318. (doi:10.1111/j.1365-2265.2006.02462.x)

Clinical Study	E Valassi, I Crespo and others	BDNF and salivary cortisone in 'cured' Cushing's syndrome	176:2	230
----------------	--------------------------------	---	-------	-----

- 12 Lindsay JR, Nansel T, Baid S, Gumowski J & Nieman LK. Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission. *Journal of Clinical Endocrinology and Metabolism* 2006 **91** 447–453. (doi:10.1210/jc.2005-1058)
- 13 Tiemensma J, Kokshoorn NE, Biermasz NR, Keijser BJ, Wassenaar MJ, Middelkoop HA & Romijn JA. Subtle cognitive impairments in patients with long-term cure of Cushing's syndrome. *Journal of Clinical Endocrinology and Metabolism* 2010 **95** 2699–2714. (doi:10.1210/jc.2009-2032)
- 14 Santos A, Resmini E, Martínez-Momblán MA, Crespo I, Valassi E, Roset M, Badia X & Webb SM. Psychometric performance of the Cushing QoL questionnaire in conditions of real clinical practice. *European Journal of Endocrinology* 2012 **167** 337–342. (doi:10.1530/EJE-12-0325)
- 15 Wagenmakers MAEM, Netea-Maier RT, Prins JB, Dekkers T, den Heijer M & Hermus ARMM. Impaired quality of life in patients in long-term remission of Cushing's syndrome of both adrenal and pituitary origin: a remaining effect of long-standing hypercortisolism? *European Journal of Endocrinology* 2012 **167** 687–695. (doi:10.1530/EJE-12-0308)
- 16 Tiemensma J, Biermasz NR, Middlekoop HAM, van der Mast RC, Romijn JA & Pereira AM. Increased prevalence of psychopathology and maladaptive personality traits after long term cure of Cushing's syndrome. *Journal of Clinical Endocrinology and Metabolism* 2010 **95** W129–E141. (doi:10.1210/jc.2010-0512)
- 17 Andela CD, van Haalen FM, Ragnarsson O, Papakokkinou E, Johannsson G, Santos A, Webb SM, Biermasz NR, van der Wee NJA & Pereira AM. Cushing's syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. *European Journal of Endocrinology* 2015 **173** R1–R14. (doi:10.1530/EJE-14-1101)
- 18 Resmini E, Santos A, Gomez-Anson B, Lopez-Mourello O, Pires P, Vives-Gilabert Y, Crespo I, Portella MJ, de Juan-Delago M & Webb SM. Hippocampal dysfunction in cured Cushing's syndrome patients, detected by 1H-MR spectroscopy. *Clinical Endocrinology* 2013 **79** 700–707. (doi:10.1111/cen.12224)
- 19 Crespo I, Granell-Moreno E, Santos A, Valassi E, Vives-Gilabert Y, De Juan-Delago M, Webb SM, Gómez-Ansón B & Resmini E. Impaired decision-making and selective cortical frontal thinning in Cushing's syndrome. *Clinical Endocrinology* 2014 **81** 826–833. (doi:10.1111/cen.12564)
- 20 van der Werff SJA, Andela CD, Pannekoek JN, Meijer OC, van Buchem MA, Rombouts SRB, van der Mast RC, Biermasz NR, Pereira AM & van der Wee NJA. Widespread reductions of white matter integrity in patients with long-term remission. *Neuroimage: Clinical* 2014 **4** 659–667. (doi:10.1016/j.nicl.2014.01.017)
- 21 Andela CD, van der Werff SJA, Pannekoek JN, van den Berg SM, Meijer OC, van Buchem MA, Rombouts SARB, van der Mast RC, Romijn JA, Tiemensma J *et al.* Smaller grey matter volumes in the anterior cingulate cortex and greater cerebellar volumes in patients with long-term remission of Cushing's disease: a case-control study. *European Journal of Endocrinology* 2013 **169** 811–819. (doi:10.1530/EJE-13-0471)
- 22 Autry AE & Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. *Pharmacological Reviews* 2012 **64** 238–258. (doi:10.1124/pr.111.005108)
- 23 Martinowich K, Manji H & Lu B. New insights into BDNF function in depression and anxiety. *Nature Neuroscience* 2007 **10** 1089–1093. (doi:10.1038/nn1971)
- 24 Givalois L, Naert G, Rage F, Ixart G, Arancibia S & Tapia-Arancibia L. A single brain-derived neurotrophic factor injection modifies hypothalamo-pituitary-adrenocortical axis activity in adult male rats. *Molecular and Cellular Neuroscience* 2004 **27** 280–295. (doi:10.1016/j.mcn.2004.07.002)
- 25 Hellhammer DH, Wüst S & Kudielka BM. Salivary cortisol as a biomarker in stress research. *Psychoneuroendocrinology* 2009 **34** 163–171. (doi:10.1016/j.psyneuen.2008.10.026)
- 26 Nieman LK, Biller BMK, Findling JW, Newell-Price J, Savage MO, Stewart PM & Montori VM. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. *Journal of Clinical Endocrinology and Metabolism* 2008 **93** 1526–1540. (doi:10.1210/jc.2008-0125)
- 27 Amlashi FG, Swearingen B, Faje AT, Nachtigall LB, Miller KK, Klibanski A, Biller BM & Tritos NA. Accuracy of late-night salivary cortisol in evaluating postoperative remission and recurrence in Cushing's disease. *Journal of Clinical Endocrinology and Metabolism* 2015 **100** 3770–3777. (doi:10.1210/jc.2015-2107)
- 28 Perogamvros I, Keevil BG, Ray DW & Trainer PJ. Salivary cortisone is a potential biomarker for serum free cortisol. *Journal of Clinical Endocrinology and Metabolism* 2010 **95** 4951–4958. (doi:10.1210/jc.2010-1215)
- 29 Perogamvros I, Owen LJ, Newell-Price J, Ray DW, Trainer PJ & Keevil BG. Simultaneous measurement of cortisol and cortisone in human saliva using liquid chromatography-tandem mass spectrometry: application in basal and stimulated conditions. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences* 2009 **877** 3771–3775. (doi:10.1016/j.jchromb.2009.09.014)
- 30 De Bono M, Harrison RF, Whitaker MJ, Eckland D, Artl W, Keevil BG & Ross RJ. Salivary cortisone reflects cortisol exposure under physiological conditions and after hydrocortisone. *Journal of Clinical Endocrinology and Metabolism* 2016 **101** 1469–1477. (doi:10.1210/jc.2015-3694)
- 31 Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO & Tabarin A. Treatment of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. *Journal of Clinical Endocrinology and Metabolism* 2015 **100** 2807–2831. (doi:10.1210/jc.2015-1818)
- 32 Raff H, Raff JL & Findling JW. Late-night salivary cortisol as a screening test for Cushing's syndrome. *Journal of Clinical Endocrinology and Metabolism* 1998 **83** 2681–2686. (doi:10.1210/jcem.83.8.4936)
- 33 Spielberger CD, Gorsuch RL & Lushene RE. *Manual for the State-Trait Anxiety Inventory (Self-Evaluation Questionnaire)*. Palo Alto, CA, USA: 7 Consultant Psychologists Press, 1970.
- 34 Beck AT, Steer RA & Brown GK. *Beck Depression Inventory 2*. San Antonio, Texas, USA: The Psychological Corporation, 1996.
- 35 Sanz J, Perdigón A & Vázquez C. The Spanish adaptation of Beck depression inventory II (BDI-II): psychometric properties in the general population. *Clínica Salud* 2003 **14** 249–280.
- 36 Radloff LS. The CES-D scale, a self-report depression scale for research in the general population. *Applied Psychological Measurement* 1977 **1** 385–401. (doi:10.1177/014662167700100306)
- 37 Watson D & Clark LA. Development and validation of brief measures of positive and negative affect: the PANAS scale. *Journal of Personality and Social Psychology* 1988 **54** 1063–1070. (doi:10.1037/0022-3514.54.6.1063)
- 38 Cohen S, Kamarck T & Mermelstein R. A global measure of perceived stress. *Journal of Health and Social Behavior* 1983 **24** 385–396. (doi:10.2307/2136404)
- 39 Badia X, Herdman M & Schiaffino A. A determining correspondence between scores on the EQ-5D 'thermometer' and a 5-point categorical rating scale. *Medical Care* 1999 **37** 671–677. (doi:10.1097/00005650-199907000-00007)
- 40 Numakawa T, Adachi N, Richards M, Chiba S & Kunugi H. Brain-derived neurotrophic factor and glucocorticoids: reciprocal influence on the central nervous system. *Neuroscience* 2013 **239** 157–172. (doi:10.1016/j.neuroscience.2012.09.073)
- 41 Calabrese F, Molteni R, Cattaneo A, Macchi F, Racagni G, Gennarelli M, Ellenbroek BA & Riva MA. Long-Term duloxetine treatment normalizes altered brain-derived neurotrophic factor

- expression in serotonin transporter knockout rats through the modulation of specific neurotrophin isoforms. *Molecular Pharmacology* 2010 **77** 846–853. (doi:10.1124/mol.109.063081)
- 42 Sen S, Duman R & Sanacora G. Serum brain-derived neurotrophin factor, depression, and antidepressant medications: meta analyses and implications. *Biological Psychiatry* 2008 **64** 527–532. (doi:10.1016/j.biopsych.2008.05.005)
 - 43 Brunoni AR, Lopes M & Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. *International Journal of Neuropsychopharmacology* 2008 **11** 1169–1180. (doi:10.1017/S1461145708009309)
 - 44 Polyakova M, Stuke K, Schuemberg K, Mueller K, Schoenknecht P & Schroeter ML. BDNF as a biomarker for successful treatment of mood disorders: a systematic and quantitative meta-analysis. *Journal of Affective Disorders* 2015 **74** 432–440. (doi:10.1016/j.jad.2014.11.044)
 - 45 Chiba S, Numakawa T, Ninomiya M, Richards MC, Wakabayashi C & Kunugi H. Chronic restraint stress causes anxiety- and depression-like behaviors, downregulates glucocorticoid receptor expression, and attenuates glutamate release induced by brain-derived neurotrophic factor in the prefrontal cortex. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 2012 **39** 112–119. (doi:10.1016/j.pnpbp.2012.05.018)
 - 46 Failla MD, Juengst SB, Arenth PM & Wagner AK. Preliminary associations between brain-derived neurotrophic factor, memory impairment, functional cognition, and depressive symptoms following severe TBI. *Neurorehabilitation and Neural Repair* 2016 **30** 419–430. (doi:10.1177/1545968315600525)
 - 47 Pan W, Banks WA, Fasold MB, Bluth J & Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. *Neuropharmacology* 1998 **37** 1553–1561. (doi:10.1016/S0028-3908(98)00141-5)
 - 48 Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, Knudsen GM & Aznar S. Blood BDNF concentrations reflect brain tissue BDNF levels across species. *International Journal of Neuropsychopharmacology* 2011 **14** 347–353. (doi:10.1017/S1461145710000738)
 - 49 Erickson KI, Prakash RS, Voss MW, Chaddock L, Heo S, McLaren M, Pence BD, Martin SA, Vieira VJ, Woods JA *et al.* BDNF is associated with age-related decline in hippocampal volume. *Journal of Neuroscience* 2010 **30** 5368–5375. (doi:10.1523/JNEUROSCI.6251-09.2010)
 - 50 Lang UE, Hellweg R, Seifert F, Schubert F & Gallinat J. Correlation between serum brain-derived neurotrophic factor level and an in vivo marker of cortical integrity. *Biological Psychiatry* 2007 **62** 530–535. (doi:10.1016/j.biopsych.2007.01.002)
 - 51 Dalby RB, Elfving B, Poulsen PH, Foldager L, Frandsen J, Videbech P & Rosenberg R. Plasma brain-derived neurotrophic factor and prefrontal white matter integrity in late-onset depression and normal aging. *Acta Psychiatrica Scandinavica* 2013 **128** 387–396. (doi:10.1111/acps.12085)
 - 52 Heim C, Ehler U & Hellhammer DH. The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. *Psychoneuroendocrinology* 2000 **25** 1–35. (doi:10.1016/S0306-4530(99)00035-9)
 - 53 Chrousos GP & Gold PW. The concepts of stress and stress system disorders. *JAMA* 1995 **267** 1244–1252. (doi:10.1001/jama.1992.03480090092034)
 - 54 Bas-Hoogendam JM, Andela CD, van der Werff JA, Pannekoek JN, van Steenbergen H, Meijer OC, van Buchem MA, Rombouts SAR, van der Mast RC, Biermasz NR *et al.* Altered neural processing of emotional faces in remitted Cushing's disease. *Psychoneuroendocrinology* 2015 **59** 134–146. (doi:10.1016/j.psyneuen.2015.05.001)
 - 55 Papoian V, Biller BMK, Webb SM, Campbell KK, Hodin RA & Phitayakorn R. Patients' perception on clinical outcome and quality of life after a diagnosis of Cushing's syndrome. *Endocrine Practice* 2015 **22** 51–67. (doi:10.4158/EP15855.OR)
 - 56 Valassi E, Santos A, Yaneva M, Tóth M, Strasburger CJ, Chanson P, Wass JA, Chabre O, Pfeifer M, Feelders RA *et al.* The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. *European Journal of Endocrinology* 2011 **165** 383–392. (doi:10.1530/EJE-11-0272)
 - 57 Pillai A, Bruno D, Sarreal AS, Hernando RT, Saint-Louis LA, Nierenberg J, Ginsberg SD, Pomara N, Mehta PD, Zetterberg H *et al.* Plasma BDNF levels vary in relation to body weight in females. *PLoS ONE* 2011 **7** e39358. (doi:10.1371/journal.pone.0039358)

Received 13 September 2016

Revised version received 11 November 2016

Accepted 22 November 2016